Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Krawczyk N et al. – HER2–positive DTCs can be detected in patients with HER2–negative tumors, even after adjuvant therapy. Such patients may benefit from (secondary) HER2–targeted therapy in an adjuvant setting.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address